Want to see PHVS full AI Analyst Report?
PHVS Stock Chart & Stats
$28.58
-$0.46(-2.39%)
At close: 4:00 PM EST
$28.58
-$0.46(-2.39%)
Day’s Range― - ―
52-Week Range$19.12 - $36.60
Previous CloseN/A
Volume14.65K
Average Volume (3M)465.98K
Market Cap
$2.41B
Enterprise Value$1.56K
Total Cash (Recent Filing)$246.96M
Total Debt (Recent Filing)$738.89K
Price to Earnings (P/E)―
Beta0.50
Next Earnings
Aug 19, 2026EPS Estimate
-0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.83
Shares Outstanding69,863,686
10 Day Avg. Volume602,880
30 Day Avg. Volume465,976
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)5.15
Price to Sales (P/S)0.00
P/FCF Ratio-10.18
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$50.90Price Target Upside78.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-2.62
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Late-stage ProgressPharvaris advancing deucrictibant into pivotal Phase 3 and regulatory submission narrows long-term development risk. A successful NDA filing and positive CHAPTER-3 topline would materially shift the company from R&D to commercialization, enabling durable revenue potential and strategic partnerships over the next 2–6 months and beyond.
Extended Cash RunwayMaterial financing completed and reported cash balances extend runway into 2028, providing the durability to finish pivotal trials and prepare U.S. commercial capabilities. This reduces immediate financing pressure, allowing execution on regulatory submissions and commercialization planning without near-term dilution risk.
Mechanism & Scientific ValidationA peer-reviewed, state-of-the-art review underscores the scientific rationale for B2 receptor antagonism and broadens clinical relevance beyond HAE. Durable scientific validation enhances the company’s competitive positioning, supports investigator uptake, and can ease regulatory discussions and future label expansion if clinical results confirm mechanism efficacy.
Bears Say
Pre-revenue, Widening LossesPharvaris remains pre-commercial with large, persistent operating losses and negative free cash flow. Sustained cash burn depletes reserves over time absent product revenue, raising structural funding and execution risk that can constrain strategic options and shareholder returns if clinical or regulatory setbacks occur.
Reliance On Equity FinancingThe company’s recent equity raises underscore dependence on capital markets to fund operations and commercialization. Repeated equity funding can dilute existing shareholders and indicates limited near-term internal cash generation, creating a structural vulnerability if market conditions or investor appetite weaken during the development timeline.
Eroding Equity & Negative ROEDeclining shareholders' equity and sharply negative returns on equity reflect cumulative losses and weak capital efficiency. A reduced equity base limits financial flexibility and increases reliance on external funding, making the company more sensitive to trial delays or adverse outcomes that could significantly impair long-term viability.
Pharvaris News
PHVS FAQ
What was Pharvaris N.V.’s price range in the past 12 months?
Pharvaris N.V. lowest stock price was $19.12 and its highest was $36.60 in the past 12 months.
What is Pharvaris N.V.’s market cap?
Pharvaris N.V.’s market cap is $2.41B.
When is Pharvaris N.V.’s upcoming earnings report date?
Pharvaris N.V.’s upcoming earnings report date is Aug 19, 2026 which is in 26 days.
How were Pharvaris N.V.’s earnings last quarter?
Pharvaris N.V. released its earnings results on May 12, 2026. The company reported $0.674 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Pharvaris N.V. overvalued?
According to Wall Street analysts Pharvaris N.V.’s price is currently Undervalued.
Does Pharvaris N.V. pay dividends?
Pharvaris N.V. does not currently pay dividends.
What is Pharvaris N.V.’s EPS estimate?
Pharvaris N.V.’s EPS estimate is -0.75.
How many shares outstanding does Pharvaris N.V. have?
Pharvaris N.V. has 69,863,686 shares outstanding.
What happened to Pharvaris N.V.’s price movement after its last earnings report?
Pharvaris N.V. reported an EPS of $0.674 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.408%.
Which hedge fund is a major shareholder of Pharvaris N.V.?
Currently, no hedge funds are holding shares in PHVS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pharvaris Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.90 (78.10% Upside)
$50.90 (78.10% Upside)
Blogger Sentiment
Bullish
PHVS Sentiment 70%
Sector Average 66%
Sector Average 66%
Insider Transactions
Sold Shares
Worth $1.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
44.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
11.71%
Trailing 12-Months
Company Description
Pharvaris N.V.
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
PHVS Stock 12 Month Forecast
Average Price Target
$50.90
▲(78.10% Upside)
Technical Analysis
Ownership Overview
2.71% Insiders
7.58% Mutual Funds
0.02% Other Institutional Investors
88.49% Public Companies and
Individual Investors